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Cerebral amyloid angiopathy (CAA) is a common cause of lobar intracerebral hemorrhage
(ICH) in elderly individuals and it is the result of the cerebrovascular deposition
of beta-amyloid (Aβ) protein. CAA is frequently found in patients with Alzheimer’s
disease (AD), although it has an independent contribution to the cognitive deterioration
associated with age. Specific apolipoproteins (Apo) have been associated with Aβ
fibrillization and clearance from the brain. In this regard, in the present study, we
analyzed the brain levels of ApoE, ApoA-I, and ApoJ/clusterin in autopsy brains from
20 post-mortem cases with CAA type I, CAA type II, with parenchymal Aβ deposits
or without Aβ deposits. Our objective was to find a possible differential pattern of
apolipoproteins distribution in the brain depending on the CAA pathological presentation.
The protein expression levels were adjusted by the APOE genotype of the patients
included in the study. We found that ApoE and ApoJ were abundantly present in
meningeal, cortical, and capillary vessels of the brains with vascular Aβ accumulation.
ApoE and ApoJ also deposited extracellularly in the parenchyma, especially in cases
presenting Aβ diffuse and neuritic parenchymal deposits. In contrast, ApoA-I staining
was only relevant in capillary walls in CAA type I cases. On the other hand, ICH was the
principal cause of death among CAA patients in our cohort. We found that CAA patients
with ICH more commonly had APOEε2 compared with CAA patients without ICH. In
addition, patients who suffered an ICH presented higher vascular ApoE levels in brain.
However, higher ApoE presence in cortical arteries was the only independent predictor of
suffering an ICH in our cohort after adjusting by age and APOE genotype. In conclusion,
while ApoE and ApoJ appear to be involved in both vascular and parenchymal Aβ
pathology, ApoA-I seems to be mainly associated with CAA, especially in CAA type I
pathology. We consider that our study helps to molecularly characterize the distribution
subtypes of Aβ deposition within the brain.
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INTRODUCTION
Cerebral beta-amyloidosis is defined as the anomalous deposition
of β-amyloid (Aβ) protein in the brain. Aβ originates by
the sequential processing of the amyloid precursor protein
(APP), primarily generating peptides of 40 and 42 amino
acids. The abnormal folding of amyloid material produces
a β-pleated sheet secondary structure, which forms highly
insoluble amyloid fibrils. In the most common form of Cerebral
Amyloid Angiopathy (CAA), insoluble Aβ accumulates in the
wall of the cortical and meningeal vessels, replacing the smooth
muscle cells, and inducing vascular degeneration. However, Aβ
can also accumulate in brain capillaries. In this regard, CAA
can be neuropathologically classified as CAA type I, which
is characterized by Aβ deposition in cerebral capillaries, or
CAA type II, where cerebral capillaries are not involved (1).
The most relevant clinical consequence of CAA is the risk
of lobar symptomatic intracerebral hemorrhages (ICH) and
microscopic cortical infarcts (2). CAA patients also present
cognitive impairment, lower perceptual speed and episodic
memory impairment, separately from the effect of Alzheimer’s
disease (AD) pathology (3). Indeed, AD is the most frequent
neurodegenerative disease, morphologically characterized by the
presence of hyperphosphorylated tau protein in the cytoplasm
of neurons and extracellular Aβ deposits forming parenchymal
plaques. Although CAA is observed in more than 90% of
AD patients (4), only a minority of AD subjects demonstrate
hemorrhages suggestive of advanced CAA (5). In fact, the
combination of factors that determine whether Aβ accumulation
occurs in parenchyma, developing into AD, or exclusively in
blood brain vessels, triggering CAA-associated ICHs, still needs
to be elucidated. It is plausible that the transport routes of
Aβ will be crucial in this process. Evidence for that is the
presence of vascular amyloid and the occurrence of cerebral
microhemorrhages and vasogenic edema when parenchymal Aβ
is mobilized by active or passive immunization in AD (6).
Specific apolipoproteins, beyond their natural role in
cholesterol metabolism, have been proposed to be involved in Aβ
transport and clearance from the brain (7, 8). Apolipoproteins
represent the protein part of lipoproteins, which classically
transport cholesterol from tissues to the liver. However, their
presence and function in the brain are not well-described. The
main apolipoproteins present in brain are apolipoprotein E
(ApoE) and apolipoprotein J (ApoJ), both of them genetically
associated with cerebral β-amyloidosis. On one hand, ApoE
has a determining role in the progression of Aβ deposition,
since having the APOEε4 allele is the major risk factor for AD
(9), as well as for CAA (10). The role of ApoJ [also known as
clusterin, (CLU)] in Aβ pathology is highlighted by genome-wide
association studies (GWAS) that found a statistical association
between a single nucleotide polymorphism within the CLU gene
and the risk of suffering AD (11). In addition, more recently,
the association between the CLU genotype and Aβ deposition,
determined by PET imaging, has been described (12). Indeed,
both ApoE and ApoJ have been shown to influence the amyloid
fibrillogenesis process and clearance in experimental models
(13–15). In this regard, apolipoprotein A-I (ApoA-I) has also
emerged as a natural chaperone able to bind Aβ and prevent its
aggregation and toxicity in vitro (16–18).
With this background, the aim of the present study was
to immunohistochemically investigate the presence of ApoE,
ApoJ, and ApoA-I in brains classified as CAA type I, CAA
type II, brains with Aβ parenchymal deposits without vascular
deposits and controls. Our hypothesis was that the expression
and distribution of this family of apolipoproteins in the brain
was modulated by the accumulation of Aβ as insoluble plaques,
deposits in cortical/meningeal vessels or capillaries. Furthermore,
we examined whether the immunopositivity of ApoE, ApoJ,
and ApoA-I in brain vessels was associated with vascular Aβ




Twenty patients with a postmortem neuropathological study
performed at the Pathology Department of Vall d’Hebron
University Hospital were selected for the study. A written and
informed consent was obtained from all patients (presenting
Aß brain deposits), or their representatives, to participate in
this research protocol before the tissue donation. For control
cases, we received the exemption of the Ethic Committee to
analyze them as anonymized samples in the context of this study.
The project was approved by the Clinical Investigation Ethical
Committee of the Vall d’Hebron University Hospital, Barcelona,
Spain PR(IR)93/2013). Patients’ characteristics and causes of
death are presented in Table 1. All samples were obtained from
2 to 20 h after decease and post-mortem specimens were fixed in
10% buffered formalin for 3–4 weeks. Macroscopic examination
was then performed, and 27 cortical and subcortical areas,
including midbrain, and cerebellum, were selected for routine
neuropathological diagnosis. Paraffin-embedded blocks were cut
into 4µm sections and stained with hematoxylin & eosin.
Aß immunohistochemistry was performed in selected areas (as
described at the end of this section). All cases were reviewed
by two neuropathologists at a multiheaded microscope. Patients
were divided into four groups according to Aß localization in the
brain (Figure 1): CAA type I patients (group 1: 6/20 cases); CAA
type II patients (group 2: 8/20 cases); patients with parenchymal
Aß deposits without vascular involvement (group 3: 3/20 cases)
and control cases with neither vascular nor parenchymal Aß
deposits (group 4: 3/20 control cases).
CAA lesions were graded following the criteria described by
Vonsattel et al. (19) and modified by Greenberg and Vonsattel
(20). Grade 0 CAA was given when no amyloid could be found in
the vessel wall. Grade 1 CAA lesions showed amyloid deposits in
otherwise normal vessels. The thickening of the vessel wall with
a stiff appearance defined a grade 2 CAA lesion, where the media
was replaced by amyloid. Grade 3 CAA showed cracking of the
vessel wall, creating a “vessel-within-vessel” appearance affecting
at least 50% of the circumference of the vessel. In grade 4 CAA
lesions, scarring of the wall was observed, with fibrinoid necrosis
and traces of intermingled amyloid deposits. Classification into
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TABLE 1 | Cause of death and patients’ characteristics.
Case Group Age Sex APOE Genotype Braak Cerad CAA type Vonsattel Cause of death
1 1 85–90 F E4/E3 V–VI C I II Intracerebral hemorrhage
2 1 75–80 F E3/E3 IV C I III Intracerebral hemorrhage
3 1 75–80 F E3/E3 I A I II Metastatic colon adenocarcinoma
4 1 70–75 M E4/E3 II B I II Intracerebral hemorrhage
5 1 80–85 M E4/E2 – – I II Intracerebral hemorrhage
6 1 75–80 M E4/E3 III C I II Heart failure
7 2 80–85 M E2/E3 IV B II II Intracerebral hemorrhage
8 2 85–90 F E2/E3 V–VI C II IV Intracerebral hemorrhage
9 2 65–70 M E3/E3 II C II II Pericarditis
10 2 90–95 F E3/E3 III C II I Mesenteric thrombosis
11 2 75–80 M E4/E3 I B II II Metastatic prostate adenocarcinoma
12 2 80–85 F E2/E3 III A II II Intracerebral hemorrhage
13 2 80–85 F E3/E3 – – II I Secondary amyloidosis
14 2 70–75 F E3/E3 – – II I Metastatic breast carcinoma
15 3 75–80 F E3/E3 I A – – Acute meningitis
16 3 55–60 F E3/E3 II C – – Ischemic stroke
17 3 75–80 F E3/E3 I B – – Acute pneumonia
18 4 50–55 M E4/E3 – – – – Pulmonary hypertension
19 4 60–65 F E3/E3 – – – – Large B cell lymphoma
20 4 70–75 M E4/E3 – – – – Multiple Myeloma
F, female; M, male.
FIGURE 1 | Classification of cases into 4 groups according to the parenchymal and vascular Aß deposition by immunostaining. Representative images of Aß
immunohistochemistry. (A) Group 1: CAA type I, defined by the presence of capillary and arterial Aß deposits. (B) Group 2: CAA type II, defined by the presence of
arterial Aß deposits without capillary involvement. (C) Group 3, characterized by the presence of parenchymal Aß deposits without vascular involvement. (D) Group 4,
defined by the absence of Aß deposits (control cases). 100x magnification.
CAA type I and CAA type II was made according to the criteria
described by Thal et al. (presence and absence of capillary Aß
deposits in types I and II, respectively) (1). Alzheimer disease
pathology was evaluated and staged according to Braak (21)
and CERAD’s criteria (22) through immunohistochemistry using
the mouse anti-human Amyloid-ß Clone 6F/3D 1:500 (Dako,
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Glostrup, Denmark) and the mouse anti-human Tau protein
Clone AT8 1:20 (Thermo Scientific, Rockford, USA).
Immunohistochemistry
To describe a representative distribution of Aβ deposits, up to
3 blocks from cortical areas, including perihippocampal cortex
in five cases, were selected in order to evaluate an equivalent
number of meningeal and cortical vessels (20–30 per case).
Brainstem and cerebellar areas were not used in this study.
Consecutive sections of the selected blocks were performed for
the detection of ApoE, ApoJ, and ApoA-I. In those samples
from patients who suffered an ICH, the immunopositivity of the
different apolipoproteins were evaluated outside the lesion.
Paraffin was removed, endogenous peroxidases were blocked
with methanol-H2O2, and non-specific binding sites were
blocked with 10% normal goat serum for 1 h. Sections were
incubated with mouse anti-human ApoE 1:200 (Clone E6D7,
Calbiochem—NE1004, Madrid, Spain), mouse anti-human ApoJ
1:1,000 (Clone 5 BD Pharmingen −552886, Madrid, Spain) and
rabbit anti-human ApoA-I 1:200 (Clone EP1368Y, Abcam—
ab52945, Cambridge, UK) for 40min at RT. Secondary antibody
(goat anti-mouse horseradish peroxidase, 1:500) was applied for
8min. Immunoreactive sites were developed with DAB solution
and serial sections were stained with hematoxylin & eosin
(H&E) to assess morphology. Meningeal and cortical vessels,
neurons, subpial astrocytes, and parenchymal deposits in cortical
and perihippocampal areas were semi-quantitatively evaluated.
Blind to the group distribution, two neuropathologists assessed
the three antibodies under a multiheaded microscope until
agreement was reached.
ApoE, ApoJ, and ApoA-I
Immunopositivity Scores
Supplemental Table 1 summarizes the scores used for the
vascular and parenchymal immunodetection. The presence of
ApoE, ApoJ, and ApoA-I immunostaining in cortical and
meningeal arteries was graded according to the percentage of
arteries showing immunopositivity: score 0 was given when no
positive arteries could be found; score 1 indicated <30% of
positive arteries; score 2 corresponded to 30–75% of positive
arteries; and score 3 indicated immunopositivity in more than
75% of the evaluated arteries. ApoE, ApoJ, and ApoA-I presence
in cortical capillaries was evaluated in 10 high-power field (HPF)
and scored as follows: score 0 when no signal was detected
in cortical capillaries; score 1 when the signal was focal (in
fewer than 50% of the capillaries); score 2 when the signal
was focal and linear (in fewer than 50% of the capillaries);
score 3 when the signal was diffuse (in more than 50% of
capillaries); and score 4 when the signal was strong and thick in
the capillaries. ApoE, ApoJ, and ApoA-I parenchymal deposits
were evaluated in 10 HPF, after detecting the hotspot for each
block, and graded according to the number of parenchymal
deposits, divided into neuritic-like plaques (with a dense core
surrounded by a clear halo and, sometimes, a neuritic corona)
and diffuse-like plaques (without any central core): score 0
indicated absence of parenchymal deposits; score 1 indicated
sparse deposits (<5/HPF); score 2 indicated a moderate number
of deposits (5–10/ HPF); and score 3 indicated frequent deposits
(>10/ HPF). Immunodetection of ApoE, ApoJ, and ApoA-I
in the cytoplasm of subpial astrocytes and pyramidal neurons
was semi-quantitatively rated as: absence, mild, moderate, or
intense expression.
APOE Genotype
Genomic DNA was extracted from formalin-fixed, paraffin-
embedded tissue using EZ1 DNA Tissue kit (48) and Bio Robot
EZ1 (Qiagen, Hilden, Germany). APOE genotypes (rs429358
and rs7412) were determined by allelic discrimination using
the SNP genotyping mixes C-3084793 and C-904973 (Applied
Biosystems, Foster City, CA, USA) and the TaqMan_Genotyping
Master Mix (Applied Biosystems) in a Rotor Gene 6000 Real-
Time PCR analyzer (Corbett Life Sciences, Valencia, CA, USA).
Statistical Analysis
Statistical analysis was conducted using SPSS package 17.0.
Clinical or pathological associations with age (continuous
variable following a normal distribution after applying the
Kolmogorov–Smirnov test) were tested using the Student’s t-test
or One-way ANOVA test, as appropriate. The rest of the
variables analyzed were considered categorical variables and the
significance of frequency differences were calculated using the
Chi Square (χ2) test or the exact test of Fisher for 2 × 2
contingency tables. Logistic regression analysis were performed
to identify independent associations with the apolipoproteins
expression. A p < 0.05 was considered statistically significant.
RESULTS
ApoE, ApoJ, and ApoA-I cerebral levels and localization were
analyzed in brains from the four different groups of patients
categorized according to the parenchymal and vascular Aß
deposition determined by immunostaining (Figure 1). Principal
demographic characteristics, AD, and CAA pathological scores
and APOE genotype of all patients included in the study can
be found in Table 1. CAA cases (encompassing groups 1 and
2) were significantly older than non-CAA cases (encompassing
groups 3 and 4) (81 ± 7 vs. 66 ± 12, p = 0.026). As expected,
ICH was the cause of death in CAA patients more often than
in non-CAA cases [50% (7/14) vs. 0% (0/6), p = 0.036]. Among
CAA patients, no differences were found in age (p = 0.983),
sex (p = 0.774), or cause of death between CAA type I (group
2) and type II (group 1) cases (p = 0.298). However, APOEε4
genotype was more represented in CAA type I patients than
in those lacking capillary CAA (type II) [67% (4/6) vs. 13%
(1/8), p = 0.036]. CAA type II cases had a slightly higher ε2
allele frequency than CAA type I, although differences were
not significant [38% (3/8) vs. 17% (1/6), p = 0.393]. APOE
genotype was not statistically associated with sex, age or other
pathological scores. However, APOE genotype was associated
with having suffered an ICH (p = 0.017). Interestingly, CAA
patients with ICH had a significantly higher APOEε2 genotype
frequency compared with CAA patients without ICH [57% (4/7)
vs. 0% (0/7), p= 0.018].
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The presence of ApoE, ApoJ, and ApoA-I in cortical
and meningeal arteries, capillaries, neuritic-like, and diffuse
parenchymal deposits was evaluated by immunohistochemistry.
Examples of immunopositivity for each case are shown in
Figure 2. Parenchymal ApoE, ApoJ, and ApoA-I presence was
also analyzed within brain cells (Supplemental Figure 1).
ApoE, ApoJ, and ApoA-I Presence in
Cerebral Arteries
In meningeal vessels, ApoE positivity was not significantly
different among groups (p = 0.307): score 3 was given to 67%
(4/6) of CAA type I, 50% (4/8) of CAA type II, and 33% (1/3) of
control cases. ApoJ levels in meningeal vessels were higher than
ApoE but was equally represented in all groups (p = 0.448). The
highest ApoJ level score (score 3) was given to 83% (5/6) of CAA
type I cases, 87% (7/8) of CAA type II cases, 67% (2/3) of brains
with parenchymal Aß deposits without Aß vascular involvement
and 67% (2/3) of control cases. ApoA-I showed a lower presence
inmeningeal vessels than ApoE or ApoJ and did not differ among
groups (p= 0.905); most of the samples received scores of 1 or 0.
Expression of ApoE, ApoJ, and ApoA-I in the meningeal arteries
was not significantly different between CAA type I and CAA
type II cases or between CAA and non-CAA cases (Figure 3A,
Supplemental Table 2). APOE genotype was not associated with
the expression of ApoE, ApoJ, and ApoA-I in meningeal arteries.
Regarding the presence of these apolipoproteins in cortical
arteries, ApoE showed a score of 3 in 50% (3/6) of CAA type I
and 63% (5/8) of CAA type II cases. Interestingly, cortical vessels
from brains with parenchymal Aß deposits without vascular Aß
involvement were not positive for ApoE (all cases scored 0),
but the differences among the 4 groups did not reach statistical
significance (p = 0.114). ApoJ vascular cortical positivity was
higher than ApoE, showing a score of 3 in all (100%, 6/6) CAA
type I cases, in 63% (2/3) of CAA type II cases and in 33%
(1/3) of brains with parenchymal Aß deposits without vascular
involvement. ApoJ expression in the cortical vessels of controls
was lower than in those cases with cerebral Aß accumulation
(p= 0.048). Presence of ApoA-I was also less frequent in cortical
vessels and was similarly distributed among groups (p = 0.441).
Expression of ApoE, ApoJ, and ApoA-I in cortical arteries was
not significantly different between CAA type I and CAA type
II cases. However, CAA brains presented a higher percentage of
ApoE-positive cortical vessels than non-CAA cases (p = 0.099),
and this was especially relevant for ApoJ (p = 0.018) (Figure 3B,
Supplemental Table 2). In addition, the presence of ApoE in
cortical arteries was nearly significantly related to the APOEε2
genotype (p= 0.058).
ApoE, ApoJ, and ApoA-I Presence in Brain
Cortical Capillaries
ApoE staining in the capillaries scored 4 in 83% (5/6) of CAA
type I cases (group 1), in which the presence was higher than
in the other groups (p = 0.002). In fact, ApoE expression
in brain capillaries was significantly more abundant in CAA
type I cases than in CAA type II cases (p = 0.004). ApoJ
positivity in the capillaries followed the same pattern as ApoE:
100% (6/6) of CAA type I cases presented the highest score
in ApoJ levels (score 4), whereas the mean score was lower in
the other groups (p = 0.001). ApoJ presence was also stronger
in microvessels affected by Aß accumulation, so levels were
higher in brain capillaries from CAA type I cases than from
CAA type II cases (p = 0.002). Interestingly, ApoA-I positivity
in the capillaries was more pronounced globally and more
homogenous between groups, although microvessels from CAA
type I samples also presented the highest score in 83% (5/6)
of the cases, which was more often than the other groups
(p = 0.006). Indeed, ApoA-I levels in brain capillaries were also
significantly higher in CAA type I cases than in CAA type II
cases (p = 0.003) (Figure 4, Supplemental Table 2). In addition,
potential associations between ApoE, ApoJ, and ApoA-I presence
in brain capillaries and APOE genotype were determined. In this
regard, only the expression of ApoE protein in capillaries was
related to APOEε4 genotype (p= 0.035), although the association
did not achieve statistical significance after the adjustment by age
and CAA subtype (odds ratio (OR) 2.32; 95% confidence interval
(CI) [0.97–5.87], p= 0.073).
ApoE, ApoJ, and ApoA-I
Parenchymal Accumulation
Frequent ApoE neuritic-like plaques (score 3) were found in
50% (3/6) of CAA type I cases, 63% (5/8) of CAA type II cases
and 67% (2/3) of cases with parenchymal Aß deposits without
vascular involvement. No ApoE neuritic-like plaques were found
in control cases (differences among the 4 groups: p = 0.002).
Similarly, 33% (2/6) of CAA type I and 63% (5/8) of CAA type
II cases showed frequent ApoJ neuritic-like plaques (score 3),
whereas there were lower scores in cases with parenchymal Aß
deposits without vascular involvement and no ApoJ neuritic-
like plaques in control cases (p = 0.002). ApoA-I deposits
were almost absent in all of the analyzed samples, and the
distribution was not different among groups (p = 0.490). No
differences were found in the number of ApoE, ApoJ, or ApoA-
I neuritic-like plaques between CAA type I and type II cases
(Figure 5A, Supplemental Table 2). APOE genotype was not
associated with the presence of ApoE, ApoJ, and ApoA-I forming
neuritic or diffuse-like parenchymal deposits
Frequent ApoE diffuse-like plaques (score 3) were found in
50% (3/6) of CAA type I cases, in 63% (5/8) of CAA type II
cases and 67% (2/3) of cases with parenchymal Aß deposits
without vascular Aß involvement. Brain samples from controls
presented fewer ApoE diffuse-like plaques, although differences
among the 4 groups were not statistically significant (p = 0.389).
The presence of ApoJ forming diffuse-like plaques was frequent
(score 3) in 33% (2/6) of CAA type I and 63% (5/8) of CAA
type II cases, in comparison with a lower detection in the rest
of the groups (p = 0.017). Although ApoE and ApoJ diffuse-
like plaques were found in 67% (2/3) of controls, groups 3 and
4 presented lower scores compared with CAA groups 1 and
2 in both cases. ApoA-I diffuse-like plaques were globally less
frequent than ApoE and ApoJ, without significant differences
among groups (p = 0.234). Presence of ApoE, ApoJ, or ApoA-
I in diffuse-like plaques was also not different between CAA
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FIGURE 2 | Representative images of brain ApoE, ApoJ, and ApoA-I immunopositivity. Serial sections were stained with anti-ApoE (A,D,G,J), anti-ApoJ (B,E,H,K),
and anti-ApoA-1 antibodies (C,F,I,L). Detection of these proteins were found in meningeal vessels (A–C), cortical vessels (D–F), cortical capillaries (G–I), and
diffuse-like (asterisks) and neuritic-like plaques (arrows) (J–L). Meningeal and cortical vessels: 100x magnification. Neuritic plaques and capillaries: 400x magnification.
type I and type II cases (Figure 5B, Supplemental Table 2).
APOE genotype was not associated with the presence of ApoE,
ApoJ, and ApoA-I forming neuritic or diffuse-like parenchymal
deposits in our cohort.
ApoE, ApoJ, and ApoA-I were expressed in the cytoplasm
of pyramidal neurons and subpial astrocytes from different
cortical and perihippocampal areas analyzed. No differences in
the number of positive cells nor in the intensity of the expression
were detected for ApoE, ApoJ, or ApoA-I among the 4 groups
analyzed or between CAA type I and CAA type II cases. ApoE,
ApoJ, and ApoA-I immunopositivity in pyramidal neurons and
subpial astrocytes are presented in Supplemental Figure 1.
Vascular ApoE, ApoJ, and ApoA-I Levels
Associated With ICH
In the cohort of analyzed postmortem brains, lobar ICH was the
principal cause of death among CAA patients (N = 7, Table 1).
Sex was not associated with ICH presence, but subjects who
suffered an ICH were older than the others (83 ± 6 vs. 73 ±
11, p = 0.040). We evaluated the possible association between
the levels of ApoE, ApoJ, and ApoA-I in brain vessels and the
occurrence of a parenchymal bleeding, although apolipoprotein
presence was evaluated far from the acute hematoma in ICH
cases. In this regard, ApoE was significantly higher in capillaries
and in meningeal and cortical arteries in those patients who
suffered an ICH (p = 0.035, p = 0.048, and p = 0.015,
respectively) (Figure 6), although ApoE immunodetection was
not associated with age. In contrast, ApoE levels in diffuse or
neuritic-like plaques were not different in patients who suffered
an ICH. ApoA-I levels in meningeal arteries were higher in ICH
patients than in the other subjects (p = 0.006). Finally, ApoJ
parenchymal presence was not statistically associated with ICH
in this cohort (Figure 6). Nevertheless, after adjusting for age and
APOE genotype, higher ApoE presence in cortical arteries was
the only independent predictor of suffering an ICH (OR, 9.40,
95% CI [1.05–84.41], p= 0.046).
DISCUSSION
It is still not completely clear why Aβ accumulates in the brain
in certain neuropathological conditions, such as AD and CAA.
Although certain inherited forms of CAA presenting cerebral
hemorrhage are associated with autosomal dominant mutations
in APP and other genes [including the cystatin C (CST3), integral
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FIGURE 3 | Distributions of ApoE, ApoJ and ApoA-I in meningeal (A) and cortical (B) arteries. 0: No staining; 1: staining in <30% of the vessels; 2: staining in
30–75% of the vessels; 3: staining in >75% of the vessels. Statistical differences were calculated using the Chi Square (χ2) test.
FIGURE 4 | Distributions of ApoE, ApoJ, and ApoA-I in cortical capillaries. 0: No staining; 1: focal and granular wall staining (<50% of the capillaries); 2: focal and
linear wall staining (<50% of the capillaries); 3: diffuse wall staining (>50% of the capillaries); 4: strong staining. Statistical differences were calculated using the Chi
Square (χ2) test.
transmembrane protein 2B (ITM2B), transthyretin and gelsolin
genes] in most cases, sporadic CAA does not clearly associate
with any genetic risk factor other than the association described
for APOEε4 (10, 23). One of the most accepted hypotheses
that tries to explain the sporadic cerebrovascular Aβ deposition
refers to “protein elimination failure” due to a deficit in protein
aggregate clearance mechanisms (24). The cerebrovasculature is
the main system responsible for the clearance of cerebral Aβ,
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FIGURE 5 | Distribution of ApoE, ApoJ and ApoA-I in neuritic plaques (A) or diffuse parenchymal deposits (B). 0: No staining; 1: 1-5/HPF; 2: 5-10/HPF; 3: >10/HPF.
Statistical differences were calculated using the Chi Square (χ2) test.
which is evacuated through perivascular drainage routes and
excluded through the blood-brain barrier (BBB). The fibrillar and
compact Aβ deposition in the brain vessel walls has been related
to abnormalities in the vasculature, which can subsequently
compromise the integrity of the BBB. Indeed, the most relevant
pathological consequence of CAA is the development of ICHs
affecting cortical and subcortical areas. Furthermore, recurrence
is a common complication in CAA patients, which results
in elevated mortality and disability rates (25). Nevertheless,
the mechanisms of vessel rupture triggering ICH due to Aβ
deposition have not been clarified either. In this regard, our
aim was to study the presence of factors that codeposit with
Aβ in brains showing different Aβ localization patterns. In
particular, we analyzed specific apolipoproteins, ApoE, ApoJ, and
ApoA-I, which may influence the insoluble deposit aggregation
and clearance (13–16) and therefore can be relevant in the
distribution of Aβ in the brain.
Brain ApoE is produced by glia (astrocytes and microglia),
pericytes, smooth muscle cells, and, to a much lesser extent,
by neurons under certain stress conditions and, potentially, in
brain endothelial cells. ApoE modulates multiple mechanistic
pathways that affect cognition, including cholesterol/lipid
homeostasis, synaptic function, glucose metabolism,
neurogenesis, mitochondrial function, tau phosphorylation,
neuronal atrophy, neuroinflammation, and the metabolism and
aggregation of Aβ (26). Previous immunohistochemical studies
in AD brains revealed the presence of ApoE in parenchymal
deposits and in the wall of brain vessels, where the ApoE level
correlated with Aβ deposits (8, 27, 28). Our results confirm some
of these previous findings, as we detected higher parenchymal
ApoE levels in brains where a previous presence of Aβ, forming
neuritic plaques, was confirmed. However, no significant
differences were found in the ApoE level in meningeal arteries
affected or not by CAA, although a tendency toward a higher
ApoE presence was observed in cortical vessels from CAA brains
than those from non-CAA brains.
Several evidences have demonstrated that APOE genotype
modifies the distribution of cerebrovascular Aβ in AD individuals
(23, 29). In this regard, we studied whether the APOE genotype
could also influence the expression of ApoE, ApoJ, and ApoA-I
in CAA cases. Although APOEε4 is a well-known risk factor for
CAA (10, 23), we could not show this association in our study,
probably because of the small sample size of the control group
(cases without Aβ pathology). However, among CAA cases, we
found that APOEε4 genotype was more represented in CAA
type I patients, whereas CAA type II patients seemed to present
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FIGURE 6 | Distribution of ApoE, ApoJ, and ApoA-I in capillaries and meningeal and cortical arteries in brains from subjects who had an intracerebral hemorrhage
(ICH) or not. Graphs represent the percentage of samples in each group (presenting ICH or not). The presence in brain capillaries was classified as 0: no staining; 1:
focal and granular wall staining (<50% of the capillaries); 2: focal and linear wall staining (<50% of the capillaries); 3: diffuse wall staining (>50% of the capillaries); 4:
strong staining. The presence in brain arteries was classified as 0: no staining; 1: staining in <30% of the vessels; 2: staining in 30–75% of the vessels; 3: staining in
>75% of the vessels. Statistical differences were calculated using the Chi Square (χ2) test.
higher APOEε2 frequency, in accordance with previous studies
(1, 30). No significant association could be found between the
immunodetection of ApoE, ApoJ, or ApoA-I and the APOE
genotype, except for a statistical trend pointing toward a link
between APOE ε2 genotype and higher presence of ApoE in
cortical arteries. In fact, in CAA-associated ICH patients, our
group previously showed higher plasma ApoE protein levels in
APOEε2 carriers (31). On the other hand, the presence of either
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APOEε4 or APOEε2 have been described to increase the risk of
lobar ICH (32). Previous pathological studies demonstrated that
APOEε2 may promote the CAA-related vessel breakdown (33),
whereas APOEε4 was associated with the amount of vascular
amyloid (10). Interestingly, in our cohort, CAA patients with
ICHmore commonly were APOEε2 carriers compared with CAA
patients without ICH, validating the results described previously
(34). In addition to this, the presence of ApoE in cortical vessels
was significantly higher in patients who suffered an ICH, after
adjusting for APOE genotype and age. This data suggests the
possible role of this apolipoprotein in the destabilization and
disruption of brain vessels, as proposed in different experimental
models (35, 36).
ApoJ is a multifunctional heterodimeric protein that acts as
a natural chaperone. ApoJ binds to Aβ in CSF and plasma
(37), and increased plasma ApoJ has been associated with a
higher prevalence and severity of AD (38). In AD brains,
ApoJ codeposits with Aβ in cerebrovascular and parenchymal
lesions (27, 39, 40). Once again, the results from our study
are in accordance with the published data, since we clearly
confirmed higher ApoJ levels in brain vessels from CAA cases
and in parenchymal neuritic-like and diffuse-like deposits in
cases presenting Aβ plaques. However, it is worth mentioning
that ApoJ and ApoE diffuse-like deposits were also found in
some control cases, where no deposits of Aβ were detected
in parenchyma. The use of more sensitive immunodetection
methods (for example, using Aβ antibodies that recognize
different epitopes) would be required to confirm these results.
The increased levels of ApoJ has been postulated as a protective
response against the aberrant accumulation of Aβ in the brain.
However, there are conflicting results in the literature regarding
the protective role of ApoJ. Knocking out CLU in a transgenic
mouse model of AD resulted in an exacerbation of vascular Aβ
deposition, whereas parenchymal Aβ deposition was remarkably
reduced (41). In another study, intraventricular administration of
an ApoJ-mimetic peptide promoted a reduction in parenchymal
and vascular Aβ accumulation and improved cognitive function
in an experimental AD model (42). Thus, the impact of the
alteration of the ApoJ level in the brain still needs to be clarified.
In our study, in contrast to ApoE, no significant association was
found between ApoJ cerebrovascular levels and the occurrence
of ICH.
Finally, ApoA-I is a major constituent of high-density
lipoprotein (HDL) in plasma and plays a crucial role in reverse
cholesterol transport. It is produced mainly in the liver and
intestine, but ApoA-I is considered to be able to cross the BBB
(43) because it has been found in CSF and throughout the brain
(44), although the mechanisms behind this trafficking are not
well-described. In fact, in AD brains, ApoA-I has been associated
with senile plaques (8, 27), although it is not clear whether
this plaque-associated ApoA-I comes from the periphery or
whether it is expressed by specific brain cells, such as endothelial
capillary cells (45). In the present study, ApoA-I was also found
in occasional brain parenchymal deposits. However, ApoA-I
positivity was less diffuse than ApoE and ApoJ in meningeal and
cortical arteries, and there was no association between ApoA-I
levels and Aβ arterial deposition.
Another important aim of our study was to determine whether
these codeposition factors were present when cases were classified
according to Aβ capillary involvement. Indeed, the clinical
relevance of the CAA neuropathological classification is under
investigation. For instance, one study found that CAA type
I seems to be associated with the severity of CAA, dementia
and severe AD-type neuropathology (46), while another study
reported that the associations of CAA with cognitive outcomes
were not driven by the presence of capillary involvement (47).
In our study, CAA capillary involvement was not associated
with the CAA or AD pathological severity. CAA subtype was
not related to ICH occurrence either. On the other hand,
the biological pattern of both CAA entities has not been
studied extensively (48). In this context, the expression of these
apolipoproteins in cerebral vessels affected by Aβ deposition was
previously described (27, 28), although no specific reports have
described a possible differential distribution pattern depending
on the CAA pathological classification. Therefore, we determined
the levels and localizations of ApoE, ApoJ, and ApoA-I in
brains classified as CAA type I or type II. We found that the
presence of the three apolipoproteins in capillaries from CAA
cases was more evident than in those from non-CAA cases.
Furthermore, the endothelial expression levels of ApoE and
ApoJ, as well as those of ApoA-I, were higher in the CAA
type I capillaries than in the CAA type II capillaries. In fact,
endothelial expression with strong and thick wall staining and,
sometimes, perivascular deposits was found in CAA type I
capillaries, while only endothelial expression without significant
wall staining was found in CAA type II capillaries. Interestingly,
our results highlight the relevant specific association between
ApoA-I presence and capillary Aβ, although whether this ApoA-
I has a peripheral origin and is attracted by the microvascular
Aβ or this is a specific expression mechanism in endothelial
cells needs to be elucidated. Furthermore, higher levels of ApoE
and ApoA-I were also detected in capillaries from patients who
suffered an ICH, independently of the CAA subtype, suggesting
the possible involvement of the accumulation of these two
apolipoproteins in the alteration of some properties associated to
the BBB integrity.
In summary, ApoE and ApoJ appear to be involved in both
vascular and parenchymal Aβ pathology, while ApoA-I seems
to be mainly associated with CAA, especially in CAA type I.
In addition, ApoE presence in cortical arteries appears as an
independent factor for the occurrence of ICH in CAA. Our study
presents important limitations, such as the small sample size of
the subgroups (principally evident for the non-CAA groups) or
the analysis of different cortical areas, which may have influenced
the apolipoprotein immunodetection rating. Further studies are
needed to evaluate the impact of the co-deposition of these
apolipoproteins in Aβ-related pathologies and in the occurrence
of CAA-associated ICH.
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